M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

Phase 1

Not yet recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Ziftomenib
Drug: Quizartinib

First Posted Date: 2025-01-10

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT06769490

Locations: 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Phase 2

Not yet recruiting

Conditions: Squamous Cell Carcinoma

Interventions: Drug: Atezolizumab
Drug: Talazoparib

First Posted Date: 2025-01-08

Last Posted Date: 2025-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 55

Registration Number: NCT06762808

Locations: 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Examining the Feasibility and Impact of a Clinic-based Food Farmacy and Digital Culinary Medicine Program Among Cancer Survivors Treated in a Safety Net Hospital

Not Applicable

Not yet recruiting

Conditions: Cancer

First Posted Date: 2025-01-07

Last Posted Date: 2025-01-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT06760754

Locations: 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Pre-surgical Tirzepatide-assisted Weight Loss in Men with Diabetes and Prostate Cancer: a Pilot Feasibility Study

Early Phase 1

Not yet recruiting

Conditions: Diabetes
Prostate Cancer

Interventions: Drug: Tirzepatide

First Posted Date: 2025-01-06

Last Posted Date: 2025-01-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06759701

Locations: 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

Phase 1

Recruiting

Conditions: Advanced Solid Malignancies

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Radiation: Radiation Therapy

First Posted Date: 2025-01-06

Last Posted Date: 2025-04-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 56

Registration Number: NCT06760481

Locations: 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

Phase 2

Recruiting

Conditions: Cancer

Interventions: Drug: Atezolizumab
Drug: Tiragolumab

First Posted Date: 2024-12-31

Last Posted Date: 2025-04-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT06754501

Locations: 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Impact of Diaphragmatic Breathing Coaching on Deep Inspiration Breath Hold Reproducibility and Organ Protection

Recruiting

Conditions: Breathing, Mouth

First Posted Date: 2024-12-24

Last Posted Date: 2025-01-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06747533

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study

Early Phase 1

Not yet recruiting

Conditions: Peripheral Neuropathy Due to Chemotherapy

Interventions: Drug: Qutenza Patch

First Posted Date: 2024-12-20

Last Posted Date: 2025-01-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT06744816

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung Cancer

Not Applicable

Recruiting

Conditions: Lung Carcinoma
Metastatic Lung Carcinoma
Stage IV Lung Cancer AJCC v8

First Posted Date: 2024-12-19

Last Posted Date: 2025-03-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT06743308

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial

Not Applicable

Not yet recruiting

Conditions: Peripheral Neuropathy Due to Chemotherapy

First Posted Date: 2024-12-17

Last Posted Date: 2024-12-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 45

Registration Number: NCT06736600

Locations: 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy